Company Overview and News

 
Apollo Minerals 'very welcome in France with flagship project progressing well'

2018-09-18 proactiveinvestors.com.au
Apollo Minerals' (ASX:AON) Hugo Schumann and IHS Markit analyst Kit Nicholls discuss the recent developments in France and reforms introduced by President Emmanuel Macron.
AON

 
Constellation rises on ASX debut

2018-07-30 businessnews.com.au
Constellation Resources, a spin-out of Apollo Minerals’ Fraser Range assets, has begun trading positively on the ASX today, after raising $7 million via an initial public offering.
AON

 
Apollo Minerals confirms "excellent" infrastructure and ground conditions at Salau mine

2018-07-09 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON) has confirmed “excellent” infrastructure and ground conditions at the Salau tungsten mine in France.
AON

 
Apollo Minerals receives French government approval to obtain 100% ownership of Couflens project

2018-06-26 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON) has received approval from the French Ministry of Economy and Finance to gain 100% ownership of the Couflens tungsten-copper-gold project in the Pyrenees.
VAR AON

 
Outlook for tungsten developers 'promising' amid tightening supply

2018-06-25 proactiveinvestors.com.au
Mark Seddon, tungsten market expert and senior manager consulting services at Argus Media is joined in the Proactive studio by Apollo Minerals' (ASX:AON) Hugo Schumann.
AON

 
Apollo Minerals advancing work on the world's highest grade tungsten mine

2018-05-17 proactiveinvestors.com.au
Capital Network's Scott Finlay offers up his views on Apollo Minerals projects across France and Spain.
AON

1
Apollo Minerals sets out to restart the world’s highest grade tungsten mine

2018-05-03 proactiveinvestors.com.au
“We have the potential to reopen the world’s highest grade tungsten mine,” says Hugo Schumann of Apollo Minerals Limited (ASX:AON).
PDZ PDZ OML AON BKY BKY

 
Apollo Minerals appoints former Berkeley Energia COO Hugo Schumann as executive director

2018-05-02 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON) has appointed Hugo Schumann as an executive director of the company with effect from 2 May 2018.
AON BKY BKY

 
Apollo Minerals appoints former Berkeley Energia COO, Hugo Schumann as an executive director

2018-05-02 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON) has appointed Hugo Schumann as an executive director of the company with effect from 2 May 2018.
AON BKY BKY

 
Apollo Minerals to expand team ahead of upcoming drill programmes

2018-05-01 proactiveinvestors.com.au
Apollo Minerals' (ASX:AON) Hugo Schumann discusses with Proactive Investors what's been described as an 'exceptionally busy' quarter.
AON

 
Apollo Minerals to beef up its board while advancing tungsten and gold assets

2018-04-30 proactiveinvestors.com.au
Apollo Minerals' (ASX:AON) Hugo Schumann discusses with Proactive Investors what's been described as an 'exceptionally busy' quarter.
AON

 
Apollo Minerals boasts of “exceptionally busy” quarter

2018-04-26 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON), in an activities report, described an “exceptionally busy” period which included a notable capital raise of A$6mln.
AON

 
Apollo Minerals intends to begin placement to fund accelerated European exploration

2018-04-06 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON) has said it will make a placement to raise A$6mln to fund accelerated exploration at its European projects.
AON

 
Apollo Minerals begins placement to accelerate European exploration

2018-04-06 proactiveinvestors.com.au
Apollo Minerals Limited (ASX:AON) has begun a placement to raise A$6mln in order to accelerate exploration at its European projects.
AON

 
Apollo Minerals raises cash to develop gold and tungsten assets

2018-04-04 proactiveinvestors.com.au
Hugo Schumann of Apollo Minerals Limited (ASX:AON) talks Proactive Investors through the company’s recent trading halt as three prestigious mining funds came on board as part of a combined A$6 million fundraise.
AON

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:AON / APOLLO MINERALS LIMITED on message board site Silicon Investor.

AONE: A123 Systems AONE: A123 Systems AONE: A123 Systems AONE AONE AONE
Aon (AOC) Aon (AOC) Aon (AOC) UMG - MediaOne Group UMG - MediaOne Group UMG - MediaOne Group
AAON AAON AAON HFC IPs: @Home, Road Runner, MediaOne Express HFC IPs: @Home, Road Runner, MediaOne Express HFC IPs: @Home, Road Runner, MediaOne Express